Filtered By:
Condition: Atrial Fibrillation
Procedure: Heart Valve Surgery

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 444 results found since Jan 2013.

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

Commentary: Postpericardial syndrome after cardiac surgery: Is it really benign?
Lehto and colleagues1 report on the long-term outcomes of postpericardiotomy syndrome (PPS) occurring after aortic valve replacement (AVR) surgery. The patient cohort was drawn from 2 large Finnish multi-institutional clinical trial databases, namely CAREAVR (Consortium of Studies in the Field of Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Valve Replacement) and CAREBANK (Cardiovascular Research Consortium---A Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients),1 in which a total of 671 AVR patients (bioprosthesis, n  = 361 and mecha...
Source: The Journal of Thoracic and Cardiovascular Surgery - March 11, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Suk Jung Choo Tags: Commentary Source Type: research

Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: A retrospective observational study.
CONCLUSIONS: In a current real-world setting in Japan, warfarin was the most commonly used treatment in AF patients with bioprosthetic valves, but there was an increasing trend of DOAC-treated patients. Further investigations are needed to confirm the efficacy and safety of DOAC in patients with bioprosthetic valves. PMID: 32156512 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 6, 2020 Category: Cardiology Authors: Izumi C, Miyake M, Amano M, Kitai T, Obayashi Y, Takegami M, Kimura T, Sugio K, Matsumoto T, Nishimura K, Furukawa Y Tags: J Cardiol Source Type: research

Concomitant atrial fibrillation ablation in patients undergoing coronary artery bypass and cardiac valve surgery
This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - February 28, 2020 Category: Cardiology Authors: Andrei Churyla, Anand Desai, Kruse Jane, James Cox, Patrick McCarthy Tags: REVIEW Source Type: research

Abbott Wins Approval for CATALYST Trial for At-Risk Stroke Patients
This study is an extremely important step in assessing the Amplatzer Amulet as an effective non-prescription drug alternative for patients with AFib who are at an increased risk for ischemic stroke." In an email sent to MD+DI, Abbott wrote, “We already have an Amulet IDE trial underway that is intended to support our submission for approval in the U.S. for Amplatzer Amulet. The newly announced CATALYST trial will support our submission for an expanded indication for Amulet as a safe and effective alternative to NOAC drugs for patients with atrial fibrillation and at risk of stroke.” Abbo...
Source: MDDI - February 3, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news

Double-Valve Heart Disease and Glomerulonephritis Consequent to Abiotrophia defectiva Endocarditis.
We present the first case of A. defectiva infective endocarditis that led to antineutrophil cytoplasmic antibody-associated glomerulonephritis. The patient was a 55-year-old man whose endocarditis affected the mitral and aortic valves. His course was complicated by atrial fibrillation, stroke, and glomerulonephritis. He was successfully treated with antibiotics and dual valve replacement. PMID: 32148451 [PubMed - in process]
Source: Texas Heart Institute Journal - January 31, 2020 Category: Cardiology Authors: Elashery AR, Stratidis J, Patel AD Tags: Tex Heart Inst J Source Type: research

Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk.
CONCLUSIONS: Our meta-analysis indicates that, in the short term, TAVI probably has little or no mortality difference compared to SAVR for severe AS in individuals with low surgical risk. Similarly, there is probably little or no difference in risk of stroke, MI, and cardiac death between the two approaches. TAVI may reduce the risk of rehospitalisation, but we are uncertain about the effects on LOS. TAVI reduces the risk of atrial fibrillation, AKI, and bleeding. However, this benefit is offset by the increased risk of PPM implantation. Long-term follow-up data are needed to further assess and validate these outcomes, esp...
Source: Cochrane Database of Systematic Reviews - December 19, 2019 Category: General Medicine Authors: Kolkailah AA, Doukky R, Pelletier MP, Volgman AS, Kaneko T, Nabhan AF Tags: Cochrane Database Syst Rev Source Type: research

Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy
ConclusionsSeptal myectomy, performed in a tertiary referral center, had a 30-day mortality rate of 0% and low morbidity rate. There was no difference between observed myectomy mortality and STS Calculator predicted risk for AVR and MV repair. It is possible that a larger sample could reveal lower mortality than STS prediction.
Source: American Heart Journal - December 19, 2019 Category: Cardiology Source Type: research

Mid-term single-centre outcomes of BioIntegral compared to Freestyle aortic conduit implantation.
CONCLUSIONS: FS and BI provide comparable clinical midterm results and hemodynamic parameters. Simplified implantation technique providing shorter cardiopulmonary bypass and operation times are advantageous for BI. PMID: 31815376 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Surgery - December 5, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Mehdiani A, Sorokin VA, Sule J, Smiris K, Stadnik D, Lichtenberg A, Blehm A Tags: J Cardiovasc Surg (Torino) Source Type: research

Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Abstract PURPOSE: The use of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) and bioprosthetic heart valve is still controversial. The aim of this study was to compare the tolerability and effectiveness of treatment with DOACs versus vitamin K antagonists (VKAs) in patients with AF and a bioprosthetic heart valve in clinical practice. METHODS: Data for this study were sourced from the multicenter, prospectively maintained AF Research Database (NCT03760874), which includes all patients with AF undergoing follow-up at participating centers through outpatient visits every 3-6 months....
Source: Clinical Therapeutics - November 13, 2019 Category: Drugs & Pharmacology Authors: Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, Parisi V, Scotti A, Nigro G, Golino P, D'Onofrio A Tags: Clin Ther Source Type: research

Predictors of Unfavourable Outcomes in Children and Adolescents Submitted to Surgical Mitral Valvuloplasty Secondary to Chronic Rheumatic Heart Disease
Conclusion: The duration of vasoactive drug use is an independent predictor for unfavourable outcomes in the immed iate and late postoperative period, while residual mitral regurgitation was associated with reoperation, and both tricuspid regurgitation and pulmonary hypertension were associated with unfavourable outcomes.Resumo Fundamento: A plastia da valva mitral, em pacientes pedi átricos com cardiopatia reumática crônica, é superior à troca valvar e vem sendo utilizada com bons resultados. Objetivo: Identificar variáveis preditoras de desfecho desfavorável em crianças e adolescentes submetidos à valvoplastia m...
Source: Arquivos Brasileiros de Cardiologia - November 5, 2019 Category: Cardiology Source Type: research

Mitral Valve Repair in Young Rheumatic Patients
Conclusion: The duration of vasoactive drug use is an independent predictor for unfavourable outcomes in the immed iate and late postoperative period, while residual mitral regurgitation was associated with reoperation, and both tricuspid regurgitation and pulmonary hypertension were associated with unfavourable outcomes.Resumo Fundamento: A plastia da valva mitral, em pacientes pedi átricos com cardiopatia reumática crônica, é superior à troca valvar e vem sendo utilizada com bons resultados. Objetivo: Identificar variáveis preditoras de desfecho desfavorável em crianças e adolescentes submetidos à valvoplastia m...
Source: Arquivos Brasileiros de Cardiologia - November 5, 2019 Category: Cardiology Source Type: research

Incidence, 30-day readmission rates and predictors of readmission after new onset atrial fibrillation who underwent transcatheter aortic valve replacement
ConclusionsIncidence of NOAF is associated with increased risk of readmissions and ischemic stroke. Future research should focus on interventions to prevent avoidable readmissions and associated morbidity and mortality.
Source: Heart and Lung: The Journal of Acute and Critical Care - November 3, 2019 Category: Respiratory Medicine Source Type: research

Antithrombotic Management After Transcatheter Aortic Valve Replacement: A Survey of Canadian Physicians
Publication date: November 2019Source: Canadian Journal of Cardiology, Volume 35, Issue 11Author(s): Seleman Reza, Natalia Pinilla, Emilie P. Belley-Côté, Kevin J. Um, Serena Sibilio, Madhu K. Natarajan, Richard P. WhitlockAbstractOptimal postprocedural antithrombotic regimen is uncertain after transcatheter aortic valve replacement (TAVR). We developed an online questionnaire on post-TAVR antithrombotic management. After research ethics board approval, we distributed the survey to TAVR implanters across Canada. A total of 24 TAVR implanters from 17 centres responded to the survey for a response rate of 75%. Dual antipla...
Source: Canadian Journal of Cardiology - November 2, 2019 Category: Cardiology Source Type: research

Early and late risk of ischemic stroke after TAVR as compared to a nationwide background population
In conclusion, TAVR was associated with an increased risk of ischemic CVE in the early phase, but not in the late phase, as compared to their matched con trols—OAC therapy reduced this early risk of ischemic CVE by half.
Source: Clinical Research in Cardiology - October 29, 2019 Category: Cardiology Source Type: research